Go to main content.

Media Release

Alcon forms strategic alliance to bring image-guided biometry to the Cataract Refractive Suite

  • End-to-end connectivity will help deliver better outcomes for cataract patients through a more efficient workflow and improved accuracy
  • MOVU’s ARGOS®SS-OCT biometer will feature Alcon’s image-guided technology for efficient integration with the Cataract Refractive Suite

Geneva, Switzerland, May 2, 2019 – Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced a strategic alliance with MOVU to bring an image-guided biometer to global markets. Based in Santa Clara, California, MOVU, a Santec company, is the manufacturer of ARGOS®, the industry-leading Swept Source Optical Coherence Tomography (SS-OCT) biometer used to measure eye parameters for patients before cataract surgery.

“We’re excited to work with MOVU to integrate the ARGOS® biometer’s diagnostic testing with Alcon’s Cataract Refractive Suite technologies inside the operating room,” said Jeannette Bankes, President and General Manager of Global Surgical Franchise at Alcon. “In doing so, our goal is to improve patient outcomes through enhanced workflow efficiency and reduced opportunities for transcription errors.”

As envisioned, MOVU’s ARGOS® biometer will gather the required diagnostic measurements by capturing a high- resolution image of each patient’s unique eye. Once captured, the same image used initially for pre-operative planning will be used to provide intra-operative guidance and post-operative assessment reducing potential sources for transcription error typically present in cataract surgery planning and execution. Further, the end-to-end connectivity between ocular biometry and the Cataract Refractive Suite aims to reduce the number of devices inside the clinical office. This results in a more efficient workflow while reducing the need for manual data entry into multiple devices.

MOVU will continue to manufacture ARGOS®, its industry-leading SS-OCT biometer while integrating Alcon’s VERION image-guidance and vision planner software directly into the biometer technology. As part of the alliance, Alcon will be the exclusive distributor of the ARGOS® biometer.

“By integrating Alcon’s image guidance and vision planning technology inside the ARGOS® biometer, we’re excited to bring a comprehensive, efficient solution for surgeons and their patients,” said Daikou Tei, President & CEO at Santec Corporation. “With ARGOS®, our goal is to simplify the cataract surgery procedure making it less manual and cumbersome so that surgeons can achieve the best outcome for patients.”

The ARGOS® biometer with image guidance by Alcon has received CE Mark and Japanese approval, and will be available in select markets including Europe during the second half of 2019. It is currently under FDA review for availability in the United States.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. In particular, our expectations could be affected by uncertainties regarding the success of our separation and spin-off from Novartis. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.

Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Alcon Media Relations

Steven Smith
+ 41 589 112 111 (Geneva)
+ 1 817 551 8057 (Fort Worth)
[email protected]

Alcon Investor Relations

Christina Cheng
+ 41 589 112 110 (Geneva)
+ 1 817 615 2789 (Fort Worth)
[email protected]